| Literature DB >> 29904105 |
Viktor Grünwald1, Berit Eberhardt2,3, Axel Bex4, Anne Flörcken5, Thomas Gauler6, Thorsten Derlin7, Martin Panzica8, Hans Roland Dürr9, Knut Achim Grötz10, Rachel H Giles3,11, Christian von Falck12, Anno Graser13, Alexander Muacevic14, Michael Staehler15.
Abstract
Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.Entities:
Mesh:
Year: 2018 PMID: 29904105 DOI: 10.1038/s41585-018-0034-9
Source DB: PubMed Journal: Nat Rev Urol ISSN: 1759-4812 Impact factor: 14.432